Your browser doesn't support javascript.
loading
Preparedness of European diagnostic microbiology labs for detection of SARS-CoV-2, March 2020.
Matheeussen, Veerle; Loens, Katherine; Lammens, Christine; Vilken, Tuba; Koopmans, Marion; Goossens, Herman; Ieven, Margareta.
Affiliation
  • Matheeussen V; Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium; Department of Microbiology, University Hospital Antwerp, Edegem, Belgium. Electronic address: veerle.matheeussen@uza.be.
  • Loens K; Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium; Department of Microbiology, University Hospital Antwerp, Edegem, Belgium.
  • Lammens C; Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium.
  • Vilken T; Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium.
  • Koopmans M; Viroscience Department, Erasmus MC, Rotterdam, the Netherlands.
  • Goossens H; Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium; Department of Microbiology, University Hospital Antwerp, Edegem, Belgium.
  • Ieven M; Department of Medical Microbiology, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Wilrijk, Belgium.
J Clin Virol ; 128: 104432, 2020 07.
Article in En | MEDLINE | ID: mdl-32422569
ABSTRACT

BACKGROUND:

To track the European spread of SARS-CoV-2, decentralized testing became necessary and test capacity needed to be expanded outside reference laboratories rapidly.

METHODS:

We assessed via an online questionnaire the preparedness of European hospital laboratories for detection of SARS-CoV-2 and listed the main drawbacks for implementation.

RESULTS:

Forty-five percent of the surveyed labs had a test in place by March 26th which is well into the first wave of the pandemic in most countries.

CONCLUSIONS:

The main implementation barriers for introduction of a SARSCoV-2 molecular assay in European diagnostic laboratories were availability of positive controls and a specificity panel.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Clinical Laboratory Techniques / Molecular Diagnostic Techniques / Pandemics / Betacoronavirus Limits: Humans Country/Region as subject: Europa Language: En Journal: J Clin Virol Journal subject: VIROLOGIA Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Clinical Laboratory Techniques / Molecular Diagnostic Techniques / Pandemics / Betacoronavirus Limits: Humans Country/Region as subject: Europa Language: En Journal: J Clin Virol Journal subject: VIROLOGIA Year: 2020 Type: Article